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What does this study add to the existing literature and how will it 
influence future clinical practice?  
This study addresses the changes in results following repair of ruptured abdominal 
aortic aneurysms at a single centre following introduction of the IMPROVE trial 
protocol.  While survival following open surgical repair remained unchanged, survival 
following endovascular repair deteriorated significantly when compared to previous 
results.  This suggests that whereas there may be a survival benefit for endovascular 
repair in selected patients, this may not be the case in an unselected cohort. 
 
Abstract 
Introduction. The first large scale randomised trial (The Immediate Management of 
the Patient with Rupture: Open Versus Endovascular repair (IMPROVE)) for 
endovascular repair of ruptured AAA (rEVAR) has recently finished recruiting 
patients. The aim of this study was to examine the impact on survival after rEVAR 
when the IMPROVE protocol was initiated in a high volume AAA centre previously 
performing rEVAR.  
Methods. One hundred and sixty-nine patients requiring emergency infrarenal AAA 
repair from January 2006 to April 2013 were included. Eighty-four patients were 
treated before (38 rEVAR, 46 open) and 85 (31 rEVAR, 54 open) were treated during 
the trial period. A retrospective analysis was performed. 
Results. Before the trial, there was a significant survival benefit for rEVAR over open 
repair (90 day mortality 13% versus 30%, P=0.04, difference remained significant out 
to 2 years post-operatively).  This survival benefit was lost after starting 
randomisation (90 day mortality 35% versus 33%, P=0.93). There was an increase in 
overall 30-day mortality from 15% to 31% (P=0.02), while there was no change for 
open repair (P=0.438). There was a significant decrease in general anaesthetic use 
(P=0.002) for patients treated during the trial.  Randomised patients had shorter 
hospital and ITU stays (P=0.006 and P=0.03 respectively). 
Conclusion. The change in survival seen during the IMROVE trial highlights the need 
for randomised rather than cohort data to eliminate selection bias. These results 
from a single centre reinforce those recently reported in IMPROVE. 
Introduction 
There has been intense debate over the role of randomised trials for endovascular 
repair of ruptured abdominal aortic aneurysms (rAAA). Since the technique was first 
described in 1994, initial uptake in specialist centres led to the publication of 
combined world data showing favourable early results.1 However, meta-analysed 
cohort data from more comprehensive literature have produced mixed results.2-4 
Some enthusiastically found short term survival benefits compared to open repair,2 
while others were more pragmatic, citing heavy selection and publication bias in 
meta-analysed studies.3;4 The implication was that true 'gold standard' evidence was 
needed before definitive recommendations on widespread adoption could be made. 
The Immediate Management of the Patient with Rupture: Open Versus Endovascular 
repair (IMPROVE) randomised trial is an attempt to provide this evidence, and has 
recently completed recruitment in the UK.5;6  
 While the 30-day results from IMPROVE have been recently reported,7 
outcomes from centres which were already performing endovascular repair of rAAA 
(rEVAR) successfully before switching to randomisation under the trial protocol are 
unknown.8 Detractors of randomised studies for rAAA have suggested that the trial is 
ethically questionable, as rEVAR results were likely to stay the same while patients 
randomised to open surgical repair (OSR) would have worse outcomes, resulting in 
net harm to the enrolled patient population.9 Proponents suggest that outcomes are 
impossible to predict, citing recognised problems with the current retrospective 
literature and the fact that previous small randomised trials for rEVAR had equivocal 
results.10;11 The aim of this study was therefore to examine rAAA outcomes in a high 
volume AAA centre previously performing rEVAR before and after the 
implementation of the IMPROVE trial protocol to assess impact on patient survival.  
Methods 
All patients were treated at Addenbrooke's Hospital as part of the local vascular 
network. The study period included January 2006 to April 2013, with follow-up until 
July 2013. This marks the time period since out of hours EVAR was available at 
Addenbrooke's. Recruitment for IMPROVE started in September 2009.5;6 All patients 
were assessed and treated by specialist vascular surgeons. If EVAR was performed, 
specialist interventional radiologists were always involved. Permissive hypotension 
at 100mmHg systolic pressure was allowed for all patients. A senior anaesthetist 
was present for all procedures including those under local anaesthetic. EVAR was 
performed with a C arm in theatre by a team consisting of at least one consultant 
vascular surgeon and one consultant vascular interventional radiologist. Post 
operatively patients went to high dependency or intensive care depending on clinical 
need. Initial experiences of rEVAR at Addenbrooke's, including results from the early 
part of the study period, have been published previously.8;12 
 A retrospective analysis of a prospectively maintained database was 
performed. Since randomising into IMPROVE this data has been held by the local 
trial co-ordinator. The database was cross-referenced with the electronic medical 
record (eMR) browser for error checking and mortality statistics. eMR is linked to the 
UK Office for National Statistics for mortality reporting. Any data not available on 
eMR was obtained directly from patient notes. No patients were lost to follow up. 
 Analysis was principally performed as treated rather than on an intention to 
treat IMPROVE protocol.  The Mann-Whitney U test was used to assess differences 
between lengths of stay. Fisher’s exact test was used to test for significance 
between individual group characteristics. Kaplan Meier estimates were used to 
examine results for five years of follow up, but two year data is reported due to the 
high attrition rate after this time.13 The Log rank test was used to compare survival 
estimates.  Confounder adjustment was performed using Cox proportional hazards 
modelling to account for differences in age; gender; history of diabetes, ischaemic 
heart disease or cerebrovascular disease; and pre-operative medications.  Data 
analysis was carried out with the R statistical package14 version 3.0.1 with the 
‘survival’ add-on package15 version 2.37-4 loaded for survival analysis.  The 
IMPROVE trial is registered as ISRCTN 48334791, and local ethical approval has 
been granted for recruitment within this trial.  The present study was carried out as 
part of routine local service evaluation within the trial and so was not deemed to 
require separate ethical approval. 
Results 
One hundred and seventy nine patients presented with ruptured AAA from January 
2006 to April 2013 (Figure 1).  Basic demographs for patients treated before and 
during IMPROVE are presented in Table 1.  Sixty-nine (39%) of these underwent 
rEVAR and one hundred (56%) underwent OSR. Ten patients (6%) were not offered 
or refused treatment and were palliated so were not analysed. Thirty-seven patients 
were randomised into the IMPROVE trial, of which thirty-five underwent surgery.  
Fifty patients (28%) were treated during the IMPROVE time period but were not 
randomised.  The most common reason for this was that they had already 
undergone CT scanning and suitability for EVAR was known at the time of referral. 
Two (3%) EVAR and four (4%) OSR died in theatre. One hundred and sixty-nine 
patients (94% of those presenting with ruptured AAA) were therefore available for 
analysis. 
 Eighty-four patients (50%) were treated for rAAA pre-IMPROVE and 85 (50%) 
have been treated during the trial. A total of 69 patients underwent rEVAR: 38 (55%) 
pre-IMPROVE and 31 (45%) during the trial. A total of 100 patients underwent OSR: 
46 pre-IMPROVE and 54 during the trial.  During the trial, sixteen patients were 
randomised to CT scan followed by EVAR if appropriate, of whom ten (63%) went on 
to have EVAR and 6 had OSR.  Nineteen patients were randomised to OSR, of 
whom sixteen (84%) had OSR and three were treated with EVAR.  The difference in 
crossover rate was not significant (p=0.25).  Patients who were randomised within 
the trial had significantly reduced total admission days (P=0.002) and ITU stay 
(P=0.01) when compared with patients who were not randomised. 
 The delay from presentation to EVAR was a median of 3 hrs 31 mins (IQR 
1hrs 24mins – 7hrs 55mins) before IMPROVE, which was significantly longer than 
for patients undergoing OSR (median 1 hr 15 mins, IQR 45mins – 2hrs 18mins; 
P<0.0001).  This improved during the trial, with no significant difference in time to 
theatre being observed between groups during the trial period (median 1hr 1 min, 
IQR 43mins – 2hrs 26mins for EVAR versus 1hr 13mins, IQR 39mins – 1hr 36mins 
for OSR; P=0.87). 
 
Survival before and during IMPROVE 
Thirty-day mortality for the 84 patients treated pre-IMPROVE was 15%. Thirty-day 
mortality for the 85 patients treated during the trial was 31%. There was a significant 
survival advantage for patients treated pre IMPROVE at 30 days (Log rank χ2 5.5, 
P=0.019), but the difference became non-significant at later time points.  This 
survival advantage was present exclusively in the rEVAR group (Log rank χ2 8.4, 
P=0.004), and persisted in this group beyond two years (Log rank χ2 4.9, P=0.03).  
This survival advantage persisted throughout follow-up after confounder adjustment 
(hazard ratio of death following OSR over rEVAR 2.8, P=0.006).  The survival benefit 
of the rEVAR group before the trial was also reflected in improved survival in 
comparison to OSR during this period (Log rank χ2 4.2, P=0.04 at two years).  This 
benefit of rEVAR over OSR has been lost since the trial started (Log rank χ2 0.1, 
P=0.79) after adjusting for confounders.  The analysis was repeated for patients 
randomised within the trial, but no survival difference between procedures was seen 
in this subgroup on an as treated basis, and there was no survival difference 
between patients who were randomised and those who were not. 
 If the survival advantage of rEVAR observed during the pre-IMPROVE period 
had been maintained during the trial, the study would have had 98% power to detect 
a survival benefit at the 5% level, so the study was adequately powered. 
Figure 2 shows survival curves pre-improve; Figure 3 shows separate survival 
curves for the different procedures. 
 
EVAR for rAAA 
Patients treated with EVAR during the IMPROVE trial were in general younger 
(median age 74 versus 79 years, P=0.03), and were more likely to be treated under 
local anaesthetic (P=0.002).  Although there was no significant difference in length of 
stay before and during the trial, there was a significant reduction in ITU stay (P=0.03) 
and total admission days (P=0.006) for the patients treated with rEVAR within the 
trial, when compared with those who were not treated within the trial.  There was a 
trend toward shorter neck length and increased neck angulation in the group treated 
during the IMPROVE trial, though these trends did not reach significance (mean±s.d. 
neck length in IMPROVE group 2.9±1.4cm versus 3.6±2.8cm, P=0.20; mean±s.d. 
neck angulation in IMPROVE group 47±22° versus 40±21°, P=0.18). 
Overall thirty-day mortality for all EVAR patients was 13%. Three, twelve and 
24 month survival was 77%, 74% and 66% respectively. Before IMPROVE these 
figures were 87%, 84% and 76%, which fell to 65%, 61% and 53% respectively 
during the trial.  Figure 3 shows comparative survival for patients undergoing EVAR 
or OSR before and during IMPROVE.  
 
Open survival 
Overall thirty-day mortality in the OSR group was 30%. Three, twelve and 24 month 
survival was 68%, 63% and 58% respectively. Figure 3 shows comparative survival 
for patients undergoing OSR before and during IMPROVE. There was no significant 
difference in mortality before IMPROVE when compared with the group treated 
during the trial (Log rank χ2 0.6, P=0.438): pre-IMPROVE cumulative survival at 3 
and 12 months was 70% and 63%; during it was 67% and 63% respectively. 
Patients undergoing OSR within the trial also had a significant reduction in ITU stay 
(P=0.047) and a reduction in total admission days, though this was not significant 
(P=0.055). 
  
EVAR follow up and reintervention 
There was no significant difference between reinterventions before and during 
IMPROVE groups (P=0.59). There were two inpatient reinterventions during the 
primary admission in each EVAR group: one type 2 endoleak requiring intervention 
due to sac expansion in both groups; and one limb occlusion requiring femoral 
crossover grafting in both groups.  
 There were eleven (29%) long term reinterventions in the group pre-
IMPROVE: 4 type 1 endoleaks, 2 type 2 endoleaks, 2 limb occlusions requiring 
crossover grafting, two limb kinks requiring stenting and one limb dislocation. There 
have been six reinterventions for the IMPROVE group (19%): 2 type 1 endoleaks, 
two infected crossover grafts requiring removal and axillo-femoral bypass, one 
occluded crossover graft requiring thrombectomy and one limb kink requiring 
stenting. 
 Discussion 
The major finding was that after starting randomisation into the IMPROVE protocol 
the survival benefit for rEVAR over OSR repair was lost. Survival for rEVAR showed 
a significant decrease while survival for OSR was unchanged compared to pre-
IMPROVE. There was a significant decrease in ITU stay (P=0.01), total admission 
days (P=0.002) and general anaesthetic use (P=0.002) for patients in the IMPROVE 
trial. 
 The strengths of this data are that the database was maintained prospectively 
from electronic medical records used to code Hospital Episode Statistics data which 
appears to be accurate for rAAA.16 The data since IMPROVE has been maintained 
by the trial investigators, again reducing concern over error in retrospective data. 
Having said this, the pre-IMPROVE data was collected retrospectively for some 
variables and is therefore subject to the usual limitations.  
Not all patients presenting since 2009 have been randomised and this may produce 
bias in the dataset. However, this was almost entirely due to either individual 
consultant selection, with some randomising all patients; or prior knowledge of 
suitability for EVAR, making them ineligible, reducing this concern to some extent.  
 Therefore, implementing the IMPROVE protocol reduced survival in rEVAR 
patients, without changing it for patients undergoing OSR. There was no reason for 
this on comparing patient demographics (Table 1). The most probable explanation is 
that this effect was due to bias from selecting patients with more suitable anatomy 
for EVAR pre-IMPROVE. This may have caused operators to push the limits of 
EVAR devices by aggressive utilisation outside the instructions for use (IFU) during 
the trial.17;18 This only adds to arguments for the value of the IMPROVE trial, as 
previously published survival results for rEVAR may be better than true outcomes 
when patients are unselected.1  
 The larger worldwide cohort studies for rEVAR show a 30-day mortality 
ranging from 21% to 32%.1;2;19 Thirty day mortality pre-IMPROVE in this centre was 
14%, which has now increased to 22%. This may mean the higher mortality centres 
were already treating more unwell or unstable patients. Importantly however, results 
of all patients presenting here have worsened since randomisation. There is an 
argument that this would always be the outcome of a randomised trial for rAAA, as 
patients with borderline suitability for rEVAR are treated in a way in which they were 
not before the trial. Pushing the limits of the technology and EVAR teams knowledge 
of rEVAR has worsened EVAR outcomes by selecting patients that will not be 
treated in this way in the future irrespective of the results of the trial.  In addition, it is 
possible that outcomes for OSR may have been subtly improved by the inclusion of 
patients with anatomy suitable for EVAR, as it has been shown that these patients 
also do better when treated with OSR20.  Indeed both neck length and angulation 
were more adverse in the EVAR group treated during the trial, although these results 
did not reach significance, so it is possible that anatomic unsuitability has resulted in 
deteriorating outcomes. 
One possible source of bias is that, while a specialist vascular surgeon was 
always involved in both assessment and treatment of all patients, those patients 
treated with rEVAR also benefitted from the involvement of a specialist interventional 
radiologist.  This may explain better early results of rEVAR before IMPROVE, 
although it cannot explain the subsequent findings. 
 A reduction in intensive care stay and hospital stay are two benefits of rEVAR 
over open repair. Although not assessed here, post-operative quality of life for 
rEVAR patients may be faster to return to preoperative levels than for open patients 
which is important in a group with such poor long term survival.21;22  As a 
consequence, even if there is no survival benefit of rEVAR over OSR, quality of life 
improvements may make it a superior therapy overall, at least for a subset of 
patients.23 
 The 30-day outcomes from the IMPROVE trial have been recently reported 
and have demonstrated no overall difference in mortality between an endovascular 
first strategy when compared to open repair.7  The reported mortalities in both 
groups were very similar to those in our patients after we started randomisation 
despite the majority of our cohort being treated outside the trial protocol.  
The Cambridge Vascular Unit was relatively high on the learning curve before 
starting randomisation, illustrated by the increasing utilisation of local anaesthetic 
and reducing time to theatre for those patients treated with rEVAR during the trial 
period, though small delays in getting patients to theatre have previously been 
shown not to impact survival significantly.24 The centre also had better survival for 
open ruptures than national UK data even before randomisation and results may be 
different in the full trial dataset.25 Additionally, crossover from EVAR to open after 
randomisation was low which may not be the case nationwide leading to a poorer 
open survival in line with previous cohort data.  
 In conclusion, the introduction of randomising patients with rAAA led to a loss 
in the survival benefit of rEVAR over OSR. This was explained by a decreased 
survival in patients treated by EVAR and unchanged survival in those undergoing 
OSR. The effect has been to worsen outcomes of rEVAR away from the results 
commonly quoted from cohort data. These findings reflect those recently reported in 
IMPROVE and selection bias may explain the low mortality rates for rEVAR in the 
historical cohort.  
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Table 1. Demographics for patients treated before and during IMPROVE 
 Before IMPROVE 
(n=84) 
During IMPROVE 
(n=85) 
P 
    
Age (Median+IQR) 78.4+7.3 75.4+11.6 0.06 
Gender (M : F) 71:13 72:13 1.0 
ITU days (Median+IQR) 3+15 2+5 0.08 
Total admission days (Median+IQR) 14+23.5 10+17 0.04 
AUI : Bifurcated graft (EVAR only) 23:15 21:10 0.62 
General : local anaesthetic (EVAR only) 31:7 14:17 0.002 
Preoperative markers:    
   Lowest Systolic BP (Median+IQR) 90+46.5 88+46 0.57 
   Highest heart rate (Median+IQR) 80+35 86+27 0.65 
   Ischaemic heart disease 42% 40% 0.88 
   Cerebrovascular disease 9% 7% 0.59 
   Diabetes 7% 6% 0.77 
   Creatinine (Median+IQR) 129+70.2 133+63 0.30 
Preoperative medication:    
   Antiplatelet / anticoagulation (%) 57 48 0.28 
   Beta blocker (%) 23 23 1.0 
   Statin (%) 52 46 0.54 
 
IQR=Inter-quartile range 
ITU=Intensive Care Unit 
AUI=Aorto-uni iliac 
Figure legends 
 
Figure 1. Flow chart showing division of patients into groups. 
 
Figure 2. Comparative survival of rAAA repair before and during the IMPROVE trial. 
The solid line shows survival pre-IMPROVE, the dashed line shows survival during 
the trial period. 
 
 
Figure 3. Comparative survival before and during IMPROVE by procedure.  The 
solid lines show survival prior to commencement of the IMPROVE trial, the dashed 
lines show survival during the trial.  Black lines show ruptured EVAR survival, grey 
lines show ruptured OSR survival. 
